35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience.
Frontline high-dose therapy (HDT) is, in 2025, the standard of care for patients with multiple myeloma (MM) who are eligible for autologous stem cell transplantation (ASCT). Prior to high-dose melphalan, induction therapy with quadruplet combinations is also proposed systematically when possible. Lenalidomide maintenance until progression is also recommended per international guidelines. This strategy has been developed over recent decades, based on results of phase 3 trials designed and conducted by different academic groups. With these therapeutic advances, the median overall survival (OS) for patients with MM has increased from 5 years in the 1990s, to over 15 years at present. Here, we present the contribution of the French myeloma cooperative group Intergroupe Francophone du Myélome (IFM) to these advances in the newly diagnosed transplant-eligible (NDTE) setting.
Authors
Moreau Moreau, Hulin Hulin, Talbot Talbot, Demarquette Demarquette, Caillot Caillot, Chalopin Chalopin, Bobin Bobin, Manier Manier, Leleu Leleu, Karlin Karlin, Caillot Caillot, Sonntag Sonntag, Feugier Feugier, Roussel Roussel, Gounot Gounot, Macro Macro, Mohty Mohty, Garderet Garderet, Tiab Tiab, Orsini-Piocelle Orsini-Piocelle, Vincent Vincent, Meuleman Meuleman, Fontan Fontan, Montes Montes, Vekemans Vekemans, Escoffre-Barbe Escoffre-Barbe, Eveillard Eveillard, Schiano de Colella Schiano de Colella, Lambert Lambert, Mary Mary, Fermand Fermand, Arnulf Arnulf, Corre Corre, Avet-Loiseau Avet-Loiseau, Facon Facon, Harousseau Harousseau, Touzeau Touzeau, Perrot Perrot
View on Pubmed